NewswireToday - /newswire/ -
Sarasota, FL, United States, 2006/12/13 - Sernova Corp President Justin Leushner believes his company’s current cell replacement therapy research could help diabetics avoid a lifetime of anti-rejection drug use.
Sernova Corp (TSX-V: SVA) President Justin Leushner told StockInterview.com in a posted audio interview, “We believe we will be able to replace (a diabetic’s) cells without a lifetime use of anti-rejection drugs.” Leushner also said that the company’s islet transplant therapy could help some nine million diabetics in America avoid daily insulin injections. Diabetes is the fifth leading cause of death in the United States, sometimes leading to amputations and blindness.
Asked about the use of pig islets in cell replacement therapy, Leushner responded, “Pig insulin is virtually identical to human insulin.” He pointed out that pig insulin has been used by diabetics for insulin injections.
Leushner praised the Edmonton Protocol islet transplant therapy as a ‘proof of concept’ and said that there was additional ‘proof of concept’ research validating the research his company was currently engaged in. Questioned about the recent criticism of the Edmonton Protocol, Leushner told StockInterview.com, “We believe our technology will be effective for the long term.”
Stockinterview.com is an online news service, which provides investigative reporting, editorial, analysis and provocative commentary of the nuclear fuel cycle, uranium mining, nuclear power, the environment and the natural resource industry. From time to time, StockInterview.com editors cover biotechnology and other sectors. StockInterview.com is best known for its 304-page trade softcover edition of “Investing in the Great Uranium Bull Market,” please visit bookstore link below.
About Sernova Corp
Sernova Corp (TSX: SVA) is a biotechnology research and development company. The company’s lead project is research into reversing insulin dependent diabetes through transplanted pig islet and Sertoli cells. SVA shares closed down two cents on Monday at C$0.41/share on more than 15,000 shares traded. Company’s website is sernovacorp.com